MARKET

AXSM

AXSM

Axsome
NASDAQ

Real-time Quotes | Nasdaq Last Sale

63.27
-0.27
-0.42%
Closed 19:43 03/27 EDT
OPEN
62.50
PREV CLOSE
63.54
HIGH
64.45
LOW
59.49
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
109.94
52 WEEK LOW
12.76
MARKET CAP
2.35B
P/E (TTM)
-31.6651
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AXSM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AXSM stock price target is 144.57 with a high estimate of 200.00 and a low estimate of 110.00.

EPS

AXSM News

More
  • The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty
  • Benzinga · 16h ago
  • Who Has Been Buying Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares?
  • Simply Wall St. · 18h ago
  • Hedge Funds Have Never Been This Bullish On Axsome Therapeutics, Inc. (AXSM)
  • Insider Monkey · 1d ago
  • Here's Why The Best Is Yet to Come for Axsome Therapeutics
  • MotleyFool.com · 5d ago

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About AXSM

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
More

Webull offers kinds of Axsome Therapeutics Inc stock information, including NASDAQ:AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions.